Tiwari RK, Shukla SS, Roy A, Satapathy T, Pandey R. Role of Serotonin in Relapse to Nicotine addiction: An Overview. Advance Research in Pharmaceuticals & Biologicals 2012;2:157-66.
Goshman LM. Clinical Toxicology of Commercial Products. Journal of Pharmaceutical Sciences 1985;74:1139-55.
Cunha OT, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev 2008;58:192-208.
Zhu PJ, Chiappinelli VA. Nicotine modulates evoked GABAergic transmission in the brain. J Neurophysiol 1999;82:3041-5.
Perkins K, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology ;184:628-36.
Hurst R, Rollema H, Bertrand D. Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther 2013;137:22-54.
Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. European journal of pharmacology 2000;393:295-314-344.
Bardo MT, Green TA, Crooks PA, Dwoskin LP. Nornicotine is self-administered intravenously by rats. Psychopharmacology 1999;146:290-6.
Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 2005;62:1142-7.
Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 2010;210:453-69.
Jain R, Varma S, Mohan D. Effects of selective dopaminergic drugs in nicotine tolerant rats. Drug Alcohol Depend 2001;63:72.
Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA, Schmidt HD. Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology 2012;37:2310-21.
Kushner HI. Toward a cultural biology of addiction. BioSocieties 2010;5:8-24.
Addicott MA, et al. Smoking withdrawal is associated with increases in brain activation during decision making and reward anticipation: a preliminary study. Psychopharmacology (Berl) 2012;219:563-73.
Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 2009;78:703-11.
Satoshi I. Brain reward circuitry beyond the mesolimbic dopamine system: A neurobiological theory. Neurosci Biobehav Rev 2010;35:129-50.
Christopher C Lapish, Sven K, Daniel D, Antonieta L, Jeremy K Seamans. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology 2007;191:609-25.
Array. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Nicotine Addiction: Past and Present. Atlanta (GA): Centers for Disease Control and Prevention (US), 2010.
Christian L, Mark AU. The Mechanistic Classification of Addictive Drugs. PLoS Med 2006;3:e437.
Bryon AD. Neurobiological Processes in Drug Reward and Addiction. Harv Rev Psychiatry 2004;12:305-20.
Alfred JR, Eric JN. Transcriptional and Epigenetic Mechanisms of Addiction. Nat Rev Neurosci 2011;12:623-37.
Hugo JO, David CG, Ernestina HG, Gerardo BM. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxid Med Cell Longev 2016;2016:9730467.
Buchta WC, Riegel AC. Chronic cocaine disrupts mesocortical learning mechanisms. Brain Research 2015;:631-6.
Deutch AY, Roth RH. The determinants of stress-induced activation of the prefrontal cortical dopamine system. Progress in Brain Research 1990;85:367-403.
Schmitt KC, Rothman RB, Reith ME. Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. Journal of Pharmacology and Experimental Therapeutics 2013;346:2-10.
Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neurosciences 2007;30:211-9.
Salas R, Cook KD, Bassetto L, De Biasi M. The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice. Neuropharmacology 2004;47:401-7.
Nick C, Ortiz BA, Heidi C, O'Neill, Michael J, Marks, et al. Varenicline Blocks β2*-nAChR-Mediated Response and Activates β4*-nAChR-Mediated Responses in Mice In Vivo Nicotine. Tob Res 2012;14:711-9.
Bernard LF, Steven RG. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol 2009;:335-67.
Neal LB. Pharmacology of Nicotine: Addiction, Smoking- Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol 2009;49:57-71.
Charles RW, Michael JM, Sharon RG. Effectiveness of Nicotinic Agonists as Desensitizers at Presynaptic α4β2- and α4α5β2-Nicotinic Acetylcholine Receptors. Nicotine Tob Res 2014;16:297-305.
Arthur LB, Alexey GM, Michael SM, Trinh L, Meaghan N, Lidia L, Jennifer S, Catherine AS, Jed ER, Mark AM. Brain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment A Randomized Trial. JAMA Psychiatry 2014;71:797-805.
Rachel EP, Robin AJL. Cellular Events in Nicotine Addiction Semin Cell. Dev Biol 2009;20:418-31.
Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Brain Res Rev 2005;48:420-37.
Yates SL, Bencherif M, Fluhler EN, Lippiello PM. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or alpha 4 beta 2 receptors to nicotine. Biochem Pharmacol 1995;50:2001-8.
Laura M, Emanuele S, Enrico C. Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus. J Physiol 2001;536:89-100.
Meaghan C, Creed NRN, Kelly RT. VTA GABA neurons modulate specific learning behaviors through the control of dopamine and cholinergic systems. Front Behav Neurosci 2014;8:8.
Danyan M, Keith G, Daniel S, Mc Gehee. Nicotine potentiation of excitatory inputs to VTA dopamine neurons. J Neurosci 2011;31:6710-20.
Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997;390:401-4.
Jain R, Mukherjee K. Biological basis of nicotine addiction. Indian Journal of Pharmacology 2003;35:281-9.
Jin HP, Soo K, Areum D, Ji HK, Ah JK. Symptomatic bradycardia due to nicotine intoxication. Rev Bras Ter Intensiva 2018;30:121-6.
Jiloha RC. Biological basis of tobacco addiction: Implications for smoking-cessation treatment. Indian J Psychiatry 2010;52:301-7.
Galindo CL, Hernandez LS, Galarraga E, Tapia D, Bargas J, Garduno J, et al. Serotoninergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholine receptors. Synapse 2008;62:601-15.
Munir GK, Thomas JG. Nicotine Modulation of Fear Memories and Anxiety: Implications for Learning and Anxiety Disorders. Biochem Pharmacol 2015;97:498-511.
Yue X, Edward FD. Tobacco/Nicotine and Endogenous Brain Opioids Prog Neuropsychopharmacol. Biol Psychiatry 2008;32:1131-8.
George EB, Alexander I, Valentina EM. Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease. Front Aging Neuro-sci 2014;6:340.
Joanna SF, Nora DV, Gene JW, Naomi P, Jean L, Colleen S, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 1996;93:14065-9.
Neal LB. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol 2009;49:57-71.
Tyndale RF, Pianezza ML, Sellers EM. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. Nicotine Tob Res 1999;1:S63-7.
Julie AT, Jeffrey AH, Dedra B, Barbara VH, Patricia NH, Rachel FT. Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. Pharmacogenet Genomics 2017;27:169-78.
Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 2008;165:1163-71.
Johnstone EC, Yudkin PL, Hey K, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;14:83-90.